Press Releases

11-13-2023	Pliant Therapeutics Presentations at The Liver Meeting® 2023 Highlight Bexotegrast, an Inhibitor of αvß6 and αvß1 Integrins, in Primary Sclerosing Cholangitis
11-09-2023	Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
11-08-2023	Pliant Therapeutics to Participate in Upcoming Investor Conferences
11-06-2023	Pliant Therapeutics Presentations at the Annual Meeting of the Society for Immunotherapy of Cancer Highlight PLN-101095, A Novel Inhibitor of Integrins αvβ8 and αvβ1
10-31-2023	Pliant Therapeutics Announces Three Presentations at the Annual Meeting of the Society for Immunotherapy of Cancer
10-19-2023	Pliant Therapeutics INTEGRIS-PSC Phase 2a Interim Data Evaluating Bexotegrast in Primary Sclerosing Cholangitis to be Highlighted in an Oral Late-Breaking Presentation at The Liver Meeting® 2023
10-16-2023	Pliant Therapeutics Appoints S. Mishima Gerhart as Chief Regulatory Officer
09-26-2023	Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from Phase 2a INTEGRIS-PSC Clinical Trial of Bexotegrast in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis
09-25-2023	Pliant Therapeutics to Host Investor Call and Webcast to Discuss Interim Results from INTEGRIS-PSC, a Phase 2a Trial in Patients with Primary Sclerosing Cholangitis
09-15-2023	Pliant Therapeutics Appoints Minnie Kuo as Chief Development Officer